• Research Scientist I

    Position: Research Scientist I (2 positions)

    Term: 1-year contract to be converted to full time

    Location: Hamilton, Ontario

    Start date: June 2019 – May 2020 (flexible)

    Deadline: Applications will be reviewed and only selected applicants will be contacted for an interview.

    How to apply: Send your CV and a cover letter to info@empiricatx.com

    About Empirica Therapeutics

    Empirica Therapeutics is developing a pipeline of innovative and transformative immunotherapies for cancers of high unmet need. Founded by Dr. Sheila Singh, a world-renowned neurosurgeon-scientist, and Dr. Jason Moffat, an international expert in functional genomics and gene-editing platforms, the company’s expertise and competitive advantage lies in its unique ability to develop candidates against the most aggressive and treatment-resistant forms of cancers, including glioblastoma (GBM) and brain metastasis (BM). 

    We are a fast-paced, dynamic and patient-focused company that will inspire you and support your career. We are looking for employees who are passionate, adaptable, creative and have a capacity for constant innovation in pursuit of company goals. 

    Responsibilities and Duties:

    • Design and develop strategies for novel T cell therapies
    • Plan and execute in vitro functional assays with human T cells
    • Create novel constructs for evaluating cellular therapy products for hard to treat solid cancer indications 
    • Maintain accurate records of research, and deliver scientific presentations and reports for internal meetings
    • Manage external resources (CRO and academic collaborations)
    • Integrate new ideas to support the company pipeline
    • Willing to wear many hats as is expected in a startup environment


    • Ph.D. in the field of Immunology, molecular biology, or related field with 0 – 3 years of experience in immuno-oncology 


    • Experience in T cell engineering, such as CAR-T or transgenic TCR T cells
    • Expertise in the characterization, culture, expansion and manipulation of T cells
    • Functional assays to measure cytokine release, proliferation and killing
    • Genetic manipulation using CRISPRs, TALENs, or ZFNs in mammalian cells
    •  Lentiviral vector design and cloning
    • Excellent oral and written communication skills
    • Strong problem-solving and analytical skills

    Salary: Commensurate with experience

    Principals only. Recruiters, please do not contact us. 

  • Empirica Therapeutics part of OBIO 2019 Capital Access Advisory Program

    Today the Ontario Bioscience Innovation Organization (OBIO) announced its 2019 Capital Access Advisory Program (CAAP). Included in this year’s program is Empirica Therapeutics, which was launched by CCAB earlier this year. 

    CAAP is designed to support “high-potential” Ontario companies to drive fundraising and lead to business and job growth. Read the detailed announcement. 

  • CCAB announces creation of Empirica Therapeutics as part of its strategy to advance new early-stage life sciences companies

    (TORONTO, February 20, 2019) –   

    The Centre for the Commercialization of Antibodies and Biologics (CCAB) today announced a license agreement with Empirica Therapeutics Inc. aimed at developing new treatments for one of the deadliest forms of brain cancer, glioblastoma. 

    Glioblastoma (GBM) is an aggressive brain cancer that, even with the best current standard of care – which includes surgery, radiation treatment and chemotherapy – has a median survivorship of only 14 months. “Glioblastoma is an unforgiving disease because it always comes back,” said Dr. Sheila Singh, co-founder and CEO of Empirica Therapeutics. “We need to look at new ways of helping these patients because current therapies are failing them.” 

    Empirica Therapeutics will lead the clinical development of novel therapeutics for GBM. The new company was formed in a partnership between CCAB and collaborators at McMaster University and the University of Toronto. Empirica Therapeutics’ lead candidate targets CD133 that is highly expressed in certain GBM cells and can potentially lead to GBM recurrence. Empirica has developed a novel CD133 immunotherapy based on the CAR-T modality that has shown promising results in pre-clinical models of GBM. This is the first product in Empirica’s pre-clinical pipeline. The company is looking to identify additional targets that can broaden applications in brain tumours and other cancers.

    Dr. Singh is a professor of surgery and biochemistry at McMaster University in Hamilton and the former division head of neurosurgery at Hamilton Health Sciences. She holds a Senior Canada Research Chair in Human Brain Cancer Stem Cell Biology. 

    Empirica was co-founded with Dr. Jason Moffat, an expert in functional genomics and gene editing. Dr. Moffat is a professor at the Donnelly Centre at the University of Toronto and a Canada Research Chair in Functional Genomics of Cancer. 

    Today’s company launch is the third as part of CCAB’s new business strategy, which aims to attract investment to create and build successful life sciences companies in Canada. “The goal of our strategy is to help translate scientific achievement and innovation into viable life sciences companies and Empirica Therapeutics is an excellent fit,” says Robert Verhagen, CEO of CCAB. “Supporting entrepreneurial scientists, like the Empirica team, helps to develop the skills and expertise that will help build and drive a sustainable biotech industry in Canada and will ultimately benefit the patients who need more effective therapies.”

    About CCAB

    The Centre for the Commercialization of Antibodies and Biologics is a national Centre of Excellence for Commercialization and Research located in Toronto, Canada. CCAB supports innovators and emerging life sciences companies through its expertise in product and business development to advance therapeutic candidates and technologies that will form the basis for company growth and sustainability. 

    About Empirica Therapeutics

    Empirica Therapeutics is developing a pipeline of innovative and transformative immunotherapies for cancers with substantial unmet need. The engine behind Empirica is a powerful functional genomics platform combined with unique patient-based models of brain cancer and recurrence that enables the discovery of new therapeutics options that have emerged from the patient’s actual tumour biology.

    For more information contact:

    Karen Ramlall
    Communications Manager, CCAB
    +1 (416) 951 4663